[1] Panahi Y, Rahimnia AR, Sharafi M,et al.Curcuminoid treatment for knee osteoarthritis: a randomized double-blind, placebo-controlled trial[J]. Phytother Res, 2015, 28(11): 1625-1631. [2] Liang P, Li SL.Advances in the clinical treatment of knee osteoarthritis[J]. Chinese Journal of Traditional Medical Traumat-ology & Orthopedics(中医骨伤科杂志), 2006, 14(3): 65-67. [3] Chinese Orthopaedic Association.Chinese guidelines for the prevention of venous thromboembolism during major orthopedic operations[J]. Chinese Journal of Joint Surgery(中华关节外科杂志),2009, 36(3): 65-71. [4] Lassen MR, Davidson BL, Gallus A, et al.The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement[J]. Journal of Thrombosis and Haemostasis, 2007, 5(12): 2368-2375. [5] Li XQ, Zhang FX, Wang SM.Guidelines for the diagnosis and treatment of deep vein thrombosis (3rd Edition)[J]. Chinese Journal of Vascular Surgery(中国血管外科杂志), 2017, 32(9): 807-812. [6] Li SQ.Antithrombotic therapy for venous thromboembolism-interpretation of the american college of chest physicians' clinical practice guidelines for evidence-based medicine (9th edition)[J]. Journal of Clinical Military Medicine(临床军医杂志), 2013, 41(6): 647-650. [7] Kubitza D, Becka M, Voith B, et al.Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor[J]. Clinical Pharmacology & Therapeutics, 2005, 78(4): 412-421. [8] Weisz C, Buetehorn U, Daehler HP, et al.Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs[J]. Xenobiotica, 2005, 35(9): 891-910. [9] Gradman AH, Wilson JT.Hypertension and diastolic heart failure[J]. Current Cardiology Reports, 2009, 11(6): 422-429. [10] Yang X, Dong SJ, Zhai SD.Meta-analysis on the efficacy and safety of rivaroxaban in the prevention of venous thromboembolism in patients after orthopaedic surgery[J]. Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2017, 33(14): 1366-1370. [11] Wen L, Han X, Zhou H.Response to novel oral anticoagulants dabigatun and rivaroxaban associated bleeding[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(1): 15-18. [12] Bao X.Introduction to the openFDA public health program[J]. China Licensed Pharmacist(中国执业药师), 2015, 12(10): 18-22. [13] DXY. FDA launches openFDA program to open health database to the public[EB/OL]. (2016-10-07) [2019-12-01]. http://yao.dxy.cn/article/77205. [14] FDA. OpenFDA/download[EB/OL].(2016-10-07) [2019-12-01]. https://open.fda.gov/downloads/. 2016. [15] Zong X, Wang YL.The enlightenment of openFDA data disclosure to China’s food and Drug regulatory data management[J]. Chinese Pharmacy(中国药房), 2017, 31(9): 976-979. [16] Duan R, Li ZX.Based on openFDA's analysis and research on the adverse reactions after the net marketing of Daggeret[J]. Chinese Journal of Hospital pharmacy(中国医院药学杂志), 2018, 38(22): 2360-2362. [17] Meng L, Tang XW, Ji HH, et al.The signal mining and evaluation of statin-related adverse reactions is based on the data mining research of the openFDA Public Data Open Project in the United States[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(2): 244-248. [18] Shi HW, Chen Y, Yao J, et al.Analysis of pirospirone ethinyle-stradiol tablets in Open FDA Public Data Program[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(9): 552-555. |